Jean-Pierre Bizzari
Independent Non-Executive DirectorDr. Jean-Pierre Bizzari, MD, is a Member of Clinical Advisory Board at Inspirna, Inc. He is Director of Aprea Therapeutics AB since August 2023. He serves as Member of Scientific Advisory Board at CARTHERA SAS. Dr. Bizzari, is Observer of Smart Immune SAS from February 16, 2024. Dr. Bizzari served as Member of Scientific Advisory Board at Oncolytics Biotech Inc. until 2024. He serves as Member of Advisory Board at Step Pharma SAS. He is an Independent Director at Aprea Therapeutics, Inc. from August 23, 2023. He is an Independent Non-Executive Director at ADC Therapeutics SA from June 30, 2022. He served as Member of Scientific Advisory Board at Seekyo SAS until November 2024. He had been an Independent Director at Compugen Ltd. since September 5, 2018 until March 1, 2022. He serves as Senior Advisor, Board Observer and Chairman of the Scientific Advisory Board at Quercis Pharma AG. He served as a Vice President for Clinical Oncology Development at sanofi-aventis from November 2004 to 2008. From 1993 to 2004. Dr. Bizzari served as Vice President, Clinical Development Oncology at Rhone-Poulenc Rorer (Aventis). He joined the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France), after working as an Assistant in the medical oncology department at La Pitié-Salpêtrière hospital in Paris. He is a Member of the scientific advisory Board of France’s National Cancer Institute and a Board Member of the European Organisation of Research and Treatment of Cancer. Prior to that, he served as Vice President of Clinical Development Oncology for Sanofi-Synthelabo from 2002 to 2004. Dr. Bizzari served as Group Head of Clinical Oncology Development at Celgene Corporation from October 2012 to December 2015. He served as Executive Vice-President at Celgene Corporation from October 2008 to December 2015. He was CMO of Celgene. Dr. Bizzari was responsible for Celgene's clinical development and operations-statistics teams across the U. S. Europe and Asia/Japan and has overseen the development and approval of a number of leading oncology products including Taxotere®, Eloxatin®, REVLIMID® (lenalidomide), VIDAZA® (azacitidine), ISTODAX® (romidepsin), Irinotecan® and ABRAXANE® (nab-paclitaxel). He served as an Independent Director at Onxeo SA since April 6, 2016 and served as its Board Observer since January 2016. He had been a Director at Pieris Pharmaceuticals, Inc. since May 12, 2015 until May 7, 2020 and serves as Advisor. He served as Independent Director of Halozyme Therapeutics, Inc. since January 2015. He has been Director of Celator Pharmaceuticals, Inc. since February 2015. He served as Independent Director at Nordic Nanovector ASA since May 19, 2016 until September 15, 2022. He serves as a Director of iTeos Therapeutics SA. He served as an Independent Director of Transgene SA since 2008 until May 2022. Since 2005, he has been a Member of the Scientific Advisory Board of the French National Cancer Research Institute. He has been Non-Executive Director of Oxford BioTherapeutics Ltd. since February 9, 2017. Dr. Bizzari also serves as a Member of the Board of Directors of Oxford BioTherapeutics Limited, NETRIS Pharma SAS and Nordic Nanovector ASA and previously served on the Board of Directors of Transgene S. A. Onxeo SA and Compugen Limited. He has been a Member of Scientific Advisory Board at oncosynergy Inc. since May 10, 2016. Dr. Bizzari serves as a Board Member of the EORTC. He serves as a Member of the Scientific Advisory Board of Netrix Pharma. He has published more than 70 articles in peer review journals and more than 160 abstracts in scientific congresses. He is an Oncologist, having trained at La Pitie-Salpetriere hospital in Paris, followed by training at the Ontario Cancer Institute and McGill Cancer Center. He is Professor emeritus of Pathology at Harvard Medical School and he was a Member of National Institute of Health (NIH) expert panels and of the medical Board of the American Asthma Foundation in the USA. Dr. Bizzari's research interests include the methodology of clinical trials and PK/PD analysis. He has trained at the Pitié-Salpêtrière Hospital in Paris, The Ontario Institute for Cancer Research and The McGill Rosalind and Morris Goodman Cancer Research Centre (formerly the McGill Cancer Center) in Montreal, Canada. He received his Medical Degree specialized in oncology from the University of Nice (France).
Positions
- Company NameADC Therapeutics SAStock CodeADCTPositionIndependent Non-Executive DirectorColleagues
- AMAmeet MallikCEO & Director
- RSRon SquarerChairman of the Board
- JIJose I. CarmonaChief Financial Officer
- MZMohamed ZakiChief Medical Officer
- LMLisa Michelle KalleboCorporate Controller & Chief Accounting Officer
- DSDavid S. EgeChief Technical Officer
- PHPeter HugVice-Chairman & Lead Independent Director
- TPTimothy P. CoughlinIndependent Non-Executive Director
